---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-23-000020"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T14:28:40.287537+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q1 net loss down 66% to $24.4M; revenue surges to $35.6M on Jazz deal; cash runway through 2026

## Summary
- Net loss $24.4M vs $72.6M in Q1 2022 (-66%); revenue $35.6M vs $1.9M, driven by Jazz collaboration.
- Cash & securities $412.4M; reaffirms 2023 net operating cash burn guidance $90-120M and cash runway through at least 2026.
- R&D expense decreased $16.6M to lower levels; Non-GAAP R&D down $14.7M.
- Will present pivotal Phase 2b zanidatamab data at ASCO (oral presentation); ZW191/ZW171 on track for IND filings in 2024.
- Board strengthened with appointment of Derek Miller, adding business development and commercial expertise.

## SEC filing metadata
- accession: 0001937653-23-000020
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/0001937653-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/zyme-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-23-000020
- JSON: https://secwatch.observer/filing/0001937653-23-000020.json
- Plain text: https://secwatch.observer/filing/0001937653-23-000020.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported first quarter ended March 31, 2023 results: net income $24.4 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Net income: $24.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics , today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/0001937653-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.